Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on: October 24,2023

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on:October 24,2023

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

Updated on: November 21,2023

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

Updated on:November 21,2023

Q and A: Is surgery best for an acoustic neuroma?

by Joseph BreenCredit: Pixabay/CC0 Public DomainI was diagnosed with an acoustic neuroma last year after I went to the doctor due to more frequent headaches. I read that surgery often is needed for th

Updated on: January 10,2024

Q and A: Is surgery best for an acoustic neuroma?

by Joseph BreenCredit: Pixabay/CC0 Public DomainI was diagnosed with an acoustic neuroma last year after I went to the doctor due to more frequent headaches. I read that surgery often is needed for th

Updated on:January 10,2024

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on: October 15,2023

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on:October 15,2023

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on: October 11,2023

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on:October 11,2023

Rise in skin cancer cases underscores importance of early detection using machine learning

In a recent review published in theLifeJournal, a group of authors reviewed image-processing techniques in machine learning (ML) for skin cancer detection using clinical images, evaluating

Updated on: October 31,2023

Rise in skin cancer cases underscores importance of early detection using machine learning

In a recent review published in theLifeJournal, a group of authors reviewed image-processing techniques in machine learning (ML) for skin cancer detection using clinical images, evaluating

Updated on:October 31,2023

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023

Using machine learning to identify undiagnosable cancers

by Bendta Schroeder,Massachusetts Institute of Technology“Machine learning tools like this one could empower oncologists to choose more effective treatments and give more guidance to their patie

Updated on: January 04,2024

Using machine learning to identify undiagnosable cancers

by Bendta Schroeder,Massachusetts Institute of Technology“Machine learning tools like this one could empower oncologists to choose more effective treatments and give more guidance to their patie

Updated on:January 04,2024

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on: October 12,2023

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on:October 12,2023

Using mathematical modeling and dynamic biomarkers to characterize metastatic disease during adaptive therapy

byH. Lee Moffitt Cancer Center & Research InstituteMathematical model overview and design. A, Simulated treatment trajectory. During the seeding/growth phase, metastases are seeded and grown

Updated on: January 04,2024

Using mathematical modeling and dynamic biomarkers to characterize metastatic disease during adaptive therapy

byH. Lee Moffitt Cancer Center & Research InstituteMathematical model overview and design. A, Simulated treatment trajectory. During the seeding/growth phase, metastases are seeded and grown

Updated on:January 04,2024

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura

Updated on: March 22,2024

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura

Updated on:March 22,2024

Pioneering mRNA-4157 Cancer Vaccines: Personalized Immunotherapy for Targeted Treatment

Updated on: June 13,2024

Pioneering mRNA-4157 Cancer Vaccines: Personalized Immunotherapy for Targeted Treatment

Updated on:June 13,2024